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Over a century ago Alois Alzheimer described the importance of neurofibrillary tangles in a 
woman who died with dementia at the age of 55 years; plaques having already been 
observed in brains by Blocq and Marinesco.  In the 1960s, Martin Roth and colleagues at 
Newcastle were first to look at the pathological basis of dementia in AD and they identified 
neuritic plaques and tangles as the key determinants of clinical dementia.  Although recent 
advances have since established the molecular basis for the pathological hallmarks of the 
disease, several studies have been contradictory in terms of whether it is amyloid or tau 
pathology that is critical in determining clinical deterioration.  Intraneuronal accumulations of 
tau within the neurofibrillary pathology of AD (tangles, neuritic plaques and dystrophic 
neurites) are closely linked with the symptoms of dementia1,2, but what initiates the process 
that leads to these intracellular lesions is uncertain.  In some cases, this might be precipitated 
by abnormal deposition of amyloid -protein while in others, some different factor may be 
involved.  The absence of tools that are sensitive enough to detect subtle clinical changes in 
key aspects of AD has made it difficult to interpret correlations with global indices of cognitive 
function. 
In this issue, Reitz et al3  (see pp XXXX-XX) describe specific losses in memory function that 
are associated with both amyloid and tau pathology in the hippocampus.  They have taken 
specific components from a neuropsychological test battery to identify three mutually 
exclusive factors (memory, visuospatial/cognitive and language functions) and examined 
these in both cross-sectional and longitudinal analyses of cases.  Braak staging shows a 
spread of tau pathology from hippocampus to medial temporal lobe and then on to parietal 
and then occipital cortices.  The original Braak study4 was based upon patients presented at 
autopsy in the absence of psychometric data.  Quantitative analysis of both hippocampus and 
neocortex reveals that the pathology of both amyloid and tau in the hippocampal formation 
was found to be associated with memory decline.  There was no association between such 
pathology in other neocortical brain regions and memory function and, conversely, no relation 
between hippocampal pathology and visuospatial or language functions was found. 
Some questions remain unanswered. This study does not claim to show the sequence of 
molecular events that lead to neuronal dysfunction.  Are the soluble oligomers of tau and 
amyloid responsible for memory impairment prior to the development of tangles and plaques?  
How might the early abnormal processing of these proteins be linked and at what stage do 
these events give rise to clinical symptoms?  These are important questions for therapeutic 
strategies if we want to prevent the disease becoming clinically overt. 
Theories on the molecular pathogenesis of AD are largely based upon cellular and animal 
models that cannot necessarily explain the regional selectivity of the disease process and so 
clinicopathological studies such as those of Reitz et al are a valuable contribution to the 
debate surrounding these theories.  
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